Interference with the innate apoptotic activity is a hallmark of neoplastic transformation and tumor formation. In this study we characterize the cytotoxic effect of phenoxodiol, a synthetic anticancer drug analog of genestein, and demonstrate the mechanism of action by which phenoxodiol affects the components of the Fas apoptotic pathway on ovarian cancer cells. Primary ovarian cancer cells, isolated from ascitic fluids of ovarian cancer patients, resistant to conventional chemotherapy, undergo apoptosis following phenoxodiol treatment. This effect is dependent upon the activation of the caspase system, inhibiting XIAP, an inhibitor of apoptosis, and disrupting FLICE inhibitory protein (FLIP) expression through the Akt signal transduction pathway. We suggest that phenoxodiol is an efficient inducer of cell death in ovarian cancer cells and sensitizes the cancer cells to Fasmediated apoptosis. We identified FLIP and XIAP signalling pathways as key factors regulating the survival of ovarian cancer cells. These findings demonstrate a novel nontoxic drug that controls FLIP/XIAP function and has the potential to eliminate tumor cells through Fasmediated apoptosis.
Introduction
Flavonoids are one of the principal plant hormones and are known to possess diverse functional roles including the regulation of plant apoptosis and cell cycle kinetics. A number of plant flavonoids show similar functional effects in animals and may be effective in inducing mitotic arrest and apoptosis. In particular, genistein, quercetin and flavopiridol have been shown to exert different effects on human cancer cells (Lamartiniere et al., 1998; Weber et al., 2000) , suggesting that this class of molecules may offer novel approaches to cancer therapy. Preliminary studies involving a number of flavonoid derivatives showed that phenoxodiol (2H-1-benzopyron-7-0,3-(hydroxy phenyl)) inhibits cell proliferation of a wide range of human cancer cell lines including leukemia, breast and prostate carcinomas, and is five to 20 times more potent than genistein (Constantinou and Husband, 2002) .
Ovarian cancer is the most lethal gynecological malignancy and is the fifth leading cause of all cancer deaths in women (Berchuck et al., 1994) . Due to its insidious onset, ovarian cancer is often discovered in advanced stages, resulting in a 20% 5-year survival rate. Current treatment of ovarian cancer includes cytoreductive surgery and combination chemotherapy using a taxane and platinum regimen. Although the initial response to chemotherapy is greater than 80%, the majority of ovarian cancer ultimately recurs due to resistance to chemotherapy (Green et al., 1984) .
The Fas/FasL system has been recognized as an important pathway not only in tissue remodelling but also in drug-induced apoptosis and its deficient activation has been implicated in the development of drug resistance (Muller et al., 1998) . We and others have shown that ovarian cancer cells are resistant to Fas activation, despite the expression of the Fas protein (Xerri et al., 1997; Mor et al., 2002) . The resistance or sensitivity to Fas-mediated apoptosis is dependent on the normal expression and function of antiapoptotic and proapoptotic molecules (Johnstone et al., 2002; Mor et al., 2002) . Without a doubt, the ability of cancer cells to evade apoptosis is an essential 'hallmark of cancer ' (Hanahan and Weinberg, 2000) . A key objective in cancer therapy is to restore sensitivity to apoptosis.
In this study, we evaluated the effect of phenoxodiol on a panel of 20 primary human ovarian cancer cell lines, isolated from the ascitic fluid of patients with ovarian cancer, and two established cell lines CP-70 and Hey cells. We demonstrated heterogeneity in the blocking elements present in ovarian cancer cells, having FLICE inhibitory protein (FLIP) and X-linked inhibitor of apoptosis (XIAP) as the main antagonists responding to signals emerging from the Akt survival pathway. We also showed that phenoxodiol induces apoptosis in ovarian cancer cells by regulating these blocking elements, suggesting that phenoxodiol may be a potential new drug in the treatment of ovarian cancer.
Results

Phenoxodiol induces cell death in primary ovarian cancer cells
Any successful cancer treatment involves an agent that induces apoptosis in the cancer cell. Therefore, we evaluated whether phenoxodiol has an effect on the viability of ovarian cancer cells. Primary ovarian cancer cell cultures, isolated from ascites of ovarian cancer patients, and the established cell lines CP-70 and Hey were treated with phenoxodiol (NV06) and three other derivatives of genestein (NV03, NV05 and NV07), and cell viability was determined using the CellTiter assay. Phenoxodiol treatment, but not NV03, NV05 or NV07, induced cell death of all the tested ovarian cancer cells (n ¼ 22) in a dose-dependent manner (shown for a selection in Figure 1a ). After phenoxodiol treatment, a significant decrease in cell viability in all the ovarian cancer cell cultures was observed at a concentration of 10 mg/ml (41.6 mm). However, phenoxodiol did not affect ovarian surface epithelial (OSE) cells' viability ( Figure 1a) . Some of the ovarian cancer cells showed an increase in the number of cells after incubation with NV-05 and NV-07, which may be because of an estrogenic effect of these compounds (data not shown).
When we compared the effect of phenoxodiol and genestein on cell viability, phenoxodiol was 30 times more effective. Thus, in CP70 cells, the IC 50 for phenoxodiol was 1.35 mm, while for genestein it was 38.95 mm.
We then evaluated the effect of phenoxodiol on colony formation of the ovarian cancer cells. As shown in Figure 1b , 4-h treatment with phenoxodiol significantly reduced the number of colonies observed after 10 days in culture.
Phenoxodiol induces apoptosis in ovarian cancer cells
To test whether the decrease in cell viability after phenoxodiol treatment was because of apoptosis, the treated cells were stained with Hoechst 33342 dye that stains condensed chromatin of apoptotic cells more brightly than the chromatin of normal cells. The chromatin was stained in the cells treated with phenoxodiol, but not in the controls (Figure 2a ). This staining correlates with the presence of cells with typical apoptotic nuclear morphology (nuclear shrinkage, DNA condensation and fragmentation). Also, phenoxodiol treatment resulted in a twofold increase in caspase-3 activity (Figure 2b ), indicating that the decreased cell viability induced by phenoxodiol is related to induction of apoptosis. No change in caspase-3 activity was found in normal OSE cells following treatment with a similar concentration of phenoxodiol ( Figure 2b ).
Phenoxodiol restores the sensitivity of ovarian cancer cells to Fas-mediated apoptosis
Our next objective was to characterize the mechanism of action of phenoxodiol-induced apoptosis in ovarian cancer cells. Chemotherapeutic agents can induce apoptosis through multiple pathways, including the extrinsic (death receptors) or intrinsic (mitochondria) pathways. We first determined whether ovarian cancer cells isolated from ascites are sensitive to Fas-mediated apoptosis, one of the main extrinsic pathways. Cells were treated with an agonistic Fas monoclonal antibody and cell viability was determined using the CellTiter 96 assay. Figure 3a shows 10 representative ovarian cancer cells treated with anti-Fas for 24 h. Fas-sensitive Jurkat T cells are included as positive controls of the assay. All ovarian cancer cell cultures (n ¼ 22) showed resistance to Fas-mediated apoptosis. In contrast, normal OSE cells undergo apoptosis when treated with anti-Fas (data not shown and Baldwin et al., 1999) . The same agonistic Fas monoclonal antibody failed to activate caspase-8 in all ovarian cancer cell cultures (Figure 3b ). Therefore, primary ovarian cancer cells are resistant to Fasmediated apoptosis possibly due to an early defect in the Fas pathway.
We investigated whether treatment with phenoxodiol would reverse the resistance of the cancer cells to Fasmediated apoptosis. Cells were pretreated with phenoxodiol 4 mm (1 mg/ml) for 24 h followed by incubation with FasL or the agonistic anti-Fas monoclonal antibody for 12 h. In the cells treated with phenoxodiol alone, cell viability decreased by 60% compared to untreated cells, while no decrease was found in the cells treated with anti-Fas or FasL alone (Figure 3c ). Phenoxodiol treatment increased the sensitivity to Fasmediated apoptosis as demonstrated by the further decrease in cell viability followed by anti-Fas (91%) or FasL (88%). These data indicate that phenoxodiol restores the sensitivity of ovarian cancer cultures to Fas-mediated apoptosis.
Phenoxodiol induces caspase-8 activation and FLIP downregulation through the Akt-pathway
Resistance to Fas-mediated apoptosis could be because of the absence of proapoptotic elements or the presence of antiapoptotic proteins blocking the Fas pathway. The expression of the main intracellular components of the Fas pathway was evaluated using Western blot analysis. The proapoptotic proteins Fas, FasL, FADD and procaspase-8, located upstream in the Fas-pathway, are all expressed at normal levels in all primary ovarian cancer cell cultures (Figures 3b  and 4a ). This suggests that the cellular resistance to Fas-mediated apoptosis is probably not caused by the absence of one of the proapoptotic proteins but rather by the presence of potential apoptotic blockers.
FLIP is an important blocker of the Fas pathway competing with caspase-8 for binding into the deathinducing signalling complex (DISC). Two FLIP splice variants, FLIP-long (FLIP L ) and FLIP-short (FLIP S ), and a cleaved form of FLIP L (FLIP C ) can be detected. These three forms of FLIP were found in the ovarian cancer cell cultures, however at different expression levels ( Figure 4a ). The high levels of FLIP expression 
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We hypothesized that phenoxodiol increases the sensitivity of ovarian cancer cells to Fas-mediated apoptosis due to caspase activation associated with the removal of FLIP's action. Ovarian cancer cells were treated with phenoxodiol (10 mg/ml) for 24 h and assessed for FLIP expression and activation of caspase-8. Phenoxodiol induced caspase-8 activation, characterized by cleavage of procaspase-8 into its p43/41 and p28 forms ( Figure 4b ) and in downregulation of the p43 form of FLIP C in all the primary cultures as well as in the CP70 and Hey cell lines. This decrease in FLIP expression corresponded with an increase in the expression of active caspase-8 (Figure 4b ).
Recent studies have reported that Akt regulates FLIP expression and blocks Fas-mediated apoptosis (Rohn et al., 1998) . Treatment with phenoxodiol for 24 h also decreased the levels of Akt expression in the ovarian cancer cells (Figure 4b ). Altogether, phenoxodiolinduced apoptosis corresponds to a reduction in Akt and FLIP expression, resulting in caspase-8 activation.
Phenoxodiol-induced apoptosis involves activation of the mitochondrial pathway
The induction of apoptosis by chemotherapeutic agents involves multiple pathways, many of them with preferential activation of the mitochondrial pathway. This pathway can be activated by a small amount of active caspase-8, resulting in caspase-9 activation. As in the same experiments previously described, we evaluated the expression and cleavage of caspase-9. Western blot analysis showed the presence of the pro-form of caspase-9 in all the ovarian cancer cells and with no cleavage of caspase-9 after anti-Fas treatment (data not shown). However, treatment with 10 mg/ml phenoxodiol resulted in cleavage of caspase-9 into its p36 form (Figure 4b ), indicating activation of the mitochondrial pathway.
Phenoxodiol treatment results in downregulation and cleavage of XIAP
XIAP is a member of intracellular antiapoptotic proteins that confers protection from death-inducing stimuli by directly blocking the activation of caspases (Deveraux et al., 1998) . However, XIAP can be inactivated by its own cleavage. To determine the fate of cellular XIAP during phenoxodiol-induced apoptotic execution, ovarian cancer cells were treated with phenoxodiol (10 mg/ml) for 24 h. Western blot analysis demonstrated the full-length (53 kDa) XIAP in the ovarian cancer cells. Phenoxodiol-treated ovarian cancer cells resulted in XIAP downregulation and cleavage to its 30 kDa inactive form (Figure 4b ). The decreased expression and cleavage of XIAP correlates with an increase in caspase-9 and -8 activation (Figure 4b ).
The levels of the pro-form of capsase-8 and XIAP showed a significant decrease only after 48 h of phenoxodiol treatment while the cleavage forms appeared as early as 12 h (Figure 4c and data not shown).
Phenoxodiol-induced apoptosis is caspase dependent
The importance of caspase activation from phenoxodiol-induced apoptosis was demonstrated by treating Figure 4d) . Similarly, the expression levels of Akt and XIAP remained equal to the nontreated control.
Tumor inhibition following phenoxodiol therapy
We examined the antitumor effect of i.p.-delivered phenoxodiol in BALB/c nude mice bearing A2780 xenografts (injected subcutaneously). When phenoxodiol was dosed i.p. at 20 mg/kg every day for 6 days, the optimal T/C was 24.7% (Po0.02), thus indicating that phenoxodiol was effective at inhibiting tumor growth (Figure 5a ). There was a 3.1-fold reduction in terminal tumour mass in phenoxodiol-treated groups when compared with control (Po0.02). No toxic side effects were noted at this dosage, and animals continued to gain weight throughout the therapeutic window (data not shown).
Discussion
The proper maintenance of the delicate balance between cell proliferation and apoptosis is essential for tissue remodelling and homeostasis in the normal ovaries. Apoptosis or programmed cell death plays an important role in OSE repair (Tilly, 2001) , follicular atresia (Hughes and Gorospe, 1991; Tilly, 1996) Although chemotherapeutic agents are widely used for the treatment of ovarian cancer, chemoresistance remains a major problem. Suppression of drug-induced apoptosis, despite the drug-induced cellular damage, is considered to be a mechanism of chemoresistance.
Targeting the factors regulating apoptosis represents a new approach for the treatment of cancer cells (Reed, 2002) . Phenoxodiol induces cell death in all studied ovarian cancer cells, including those cells resistant to conventional agents such as paclitaxel and carboplatin (Flick et al., in preparation) .
We have characterized the cytotoxic effect of phenoxodiol on ovarian cancer cells, and demonstrated that (1) this is a highly efficient drug inducing apoptosis in all studied ovarian cancer cells and (2) this apoptotic effect is due to the regulation of the Akt-FLIP-XIAP pathway. Furthermore, we demonstrated that the successful inactivation of FLIP and XIAP by phenoxodiol restores the sensitivity of ovarian cancer cells to Fas-mediated apoptosis.
The decrease in cell viability after phenoxodiol treatment was due to the induction of apoptosis as demonstrated by chromatin condensation and caspase activation. Mechanisms of apoptosis have been classified into two main groups: an intrinsic or mitochondrial apoptotic pathway and an extrinsic or receptormediated pathway. The extrinsic pathway is exemplified by a receptor-initiated proapoptotic signal, such as that initiated by Fas (Green and Evan, 2002) .
The Fas pathway is one of the main pathways mediating tissue remodelling in reproductive organs, including the mammary gland and the ovaries (Mori et al., 1997; Quirk et al., 1997; Song et al., 2000; Sapi et al., 2002) . We have shown that the expression of Fas and FasL, in normal tissues, responds to the cyclic hormonal changes and that the apoptotic pathway is activated as a result of hormone withdrawal or decrease in estrogen and progesterone (Song et al., 2000 (Song et al., , 2002 Sapi et al., 2002) . In this way, the Fas/FasL system controls cell number in the reproductive tissues by eliminating cells through apoptosis. Disruption of this pathway can lead to excessive tissue proliferation and cancer. Contrary to normal ovarian cells, ovarian cancer cells are resistant to Fas-mediated apoptosis (Baldwin et al., 1999) and do not respond to hormone withdrawal (Song et al., , 2002 .
The initiation of caspase activation was believed to be the 'point of no return', after which the cell was irreversibly committed to cell death. New evidence indicates that activation of caspases can be controlled at different levels (Salvesen and Duckett, 2002) . We evaluated the effect of phenoxodiol on the activators and inhibitors of apoptosis as well as the effector caspases. One of the early inhibitors, FLIP, contains Phenoxodiol and apoptosis of ovarian cancer cells M Kamsteeg et al caspase-8-like death effector domains (DEDs) and competes with procaspase-8 for recruitment into the DISC. Multiple splice variants of FLIP have been reported, but so far only two forms of FLIP, FLIP L and FLIP S , can be detected at the protein level . FLIP L and FLIP S inhibit different steps of caspase-8 activation at the DISC (Krueger et al., 2001) .
Interestingly, high expression levels of FLIP were observed in the ovarian cancer cells, which may explain the absence of caspase-8 activation upon Fas stimulation (Kirchhoff et al., 2000; Krueger et al., 2001) . Phenoxodiol-induced apoptosis was related to a decrease in the expression of the p43 form of FLIP. However, this effect was not at the RNA level (no changes in FLIP mRNA levels following phenoxodiol treatment were identified), suggesting the involvement of ubiquitination and proteosome-dependent degradation of FLIP, as shown by a recent study where PPARg modulators induce ubiquitination of FLIP, without concomitant reduction in FLIP RNA (Kim et al., 2002) . These results indicate the existence of another intracellular pathway that may regulate FLIP expression.
Considerable crosstalk exists between the extrinsic and intrinsic pathways. Caspase-8 can activate Bid, which then facilitates cytochrome c release from the mitochondria followed by caspase-9 and -3 activation . The apoptotic effect of phenoxodiol seems to involve the extrinsic (caspase-8) and the intrinsic pathway (capase-9). Caspase-9 and its cofactor Apaf1 have been found to be essential downstream components of p53 in myc-induced apoptosis (Soengas et al., 1999) . Inactivation of Apaf1 was shown to be associated with chemoresistance in metastatic melanoma (Soengas et al., 2001) . Therefore, blocking caspase-9 function in ovarian cancer cells may constitute a mechanism of drug resistance that phenoxodiol is able to overcome, but how?
An important factor controlling caspase-9 function is a family of proteins known as inhibitors of apoptosis (IAPs). The IAP proteins are endogenous inhibitors of the terminal or effector caspases and provide a mechanism for limiting or halting the cascade (Salvesen and Duckett, 2002). When we checked for the expression of XIAP in our panel of ovarian cancer cells, we found that all of them express high levels of this inhibitor. These findings correlate with previous studies showing that IAPs are highly expressed in many tumors and contribute to the resistance of cancers to apoptosis (Deveraux et al., 1998; Salvesen and Duckett, 2002) .
Treatment of the ovarian cancer cells with phenoxodiol induces the inactivation of XIAP characterized by the appearance of an B30-kDa protein which corresponds to the cleavage of XIAP (Figure 4b) (Deveraux et al., 1999) . Deveraux et al. (1999) have demonstrated that the cleavage of XIAP may be one of the mechanisms by which cell death programs circumvent the antiapoptotic barrier posed by XIAP. This may explain our findings of caspase-9 activation after phenoxodiol treatment. Furthermore, it was shown that incubation of XIAP with purified recombinant caspase-8 results in XIAP cleavage (Deveraux et al., 1999) . The first effect that we found with phenoxodiol treatment is caspase-8 activation followed by caspase-9. We, therefore, propose that the decrease in FLIP expression allows caspase-8 activation which results in the cleavage/ inactivation of XIAP, and consequently removes the blocking of caspase-9 and -3, allowing apoptosis. This is confirmed by our finding that incubation of the cancer cells with a general caspase inhibitor prior to phenoxodiol treatment inhibits XIAP cleavage and apoptosis.
The next question is the mechanism of action by which phenoxodiol removes FLIP and allows caspase-8 to activate the apoptotic cascade. The balance between proliferation and cell death is clearly exemplified by the antiapoptotic effect of survival signals such as the phosphatidyl-inositol 3-kinase (PI3 K)/Akt pathway. The PI3K/Akt pathway is crucial for protection against apoptosis by various mechanisms, including the activation of NF-kB, phosphorylation of Bcl-2 antagonist of cell death (BAD), inhibition of caspase-9 and suppression of FasL. Akt translocates to the nucleus where it may contribute to the regulation of the transcription of genes mediating cell survival. A possible mechanism by which Akt functions as a promoter of survival is through the induction of FLIP expression and blocking the extrinsic apoptotic pathway (Panka et al., 2001; Suhara et al., 2001) . Also, in this study, high levels of FLIP were found in all the ovarian cancer cells. When we evaluated the effect of phenoxodiol on Akt, we found a clear inhibition of its expression, followed by a decrease in FLIP expression and reversal of the sensitivity to Fas-mediated apoptosis.
The in vitro studies were confirmed by the results in vivo. Phenoxodiol treatment was active against A2780 ovarian cancer xenografts, reducing by B80% tumor mass in relation to the control. These data show that the antitumor activity exerted by phenoxodiol is effective, in vivo, in treating cancer cells.
In summary, the studies described above highlight the fact that disruption of apoptosis can promote tumor initiation, progression and treatment resistance and, therefore, emphasize the importance of understanding the underlying alterations that influence apoptosis during tumorigenesis. It is a fact that anticancer agents induce apoptosis in normal tissues as well as in tumors, making the development of new treatments for ovarian cancer that can specifically restore apoptosis in cancer cells without affecting the normal tissues a crucial objective. Phenoxodiol has proven to accomplish these objectives both in vitro and in vivo by mediating the removal of blockers of apoptosis and renewing their sensitivity to cell death. Our next task is to prove whether it is also effective in patients with ovarian cancer.
Materials and methods
Isolation of primary ovarian cancer cells and cell culture
Ascites collected from patients were centrifuged for 20 min at 300 Â g to pellet cells. The cells were washed with Cellgro (Mediatech, Herndon, VA, USA), and subjected to gradient centrifugation using Lymphocyte Separation Medium (ICN Biomedicals Inc.) to separate cancer cells and white blood cells (mononuclear cells) from red blood cells. The mononuclear cell-containing layer was collected and incubated with an anti-CD45 mAb conjugated to magnetic beads (Dynabeads 450, Dynal, Oslo, Norway) at 41C with rotation for 30 min. Following this incubation, the cells were placed into a magnetic field and the unbound epithelial cells were collected, washed and placed into culture media. The purity of the epithelial ovarian cancer cells was 100% as determined by immunostaining for cytokeratin (Sigma). Cancer cells were cultured in 50% 199 medium and 50% 105 medium (Sigma, St Louis, MT), supplemented with 15% FBS (Gemini Bioproducts), 4 ng/ml EGF (Sigma), 1000 U/ml penicillin, 100 mg/ml streptomycin, 10 mm HEPES, 100 nm nonessential amino acids and 1 mm sodium pyruvate (Gibco, Carlsbad, CA, USA). Malignancy of the isolated ovarian cells was confirmed with Pap staining by the Department of Pathology (Yale University). Experiments were carried out within five passages. Jurkat cells were grown in RPMI (Gibco), supplemented with 10% FBS (Gemini Bioproducts), 1000 U/ml penicillin, 100 mg/ ml streptomycin, 10 mm HEPES, 100 nm nonessential amino acids and 1 mm sodium pyruvate (Gibco).
Stimulation of Fas-mediated apoptosis and phenoxodiol treatment
The sensitivity to Fas-mediated apoptosis was evaluated as previously described . In short, cells were treated in the presence or absence of 500 ng/ml Fas-antibody (PharMingen, San Diego, CA, USA) in Optimem for 24 h or with 0.1, 1 or 10 mg/ml phenoxodiol, NV03, NV05 or NV07 in Optimem for 24 h. For treatment with phenoxodiol and caspase inhibitors, 10 mg/ml phenoxodiol was used alone, or in combination with 20 mm general caspase-inhibitor Z-VAD-FMK (PharMingen) and incubated for 24 h.
Cell viability assay
Cells (10 000) were plated per well in a 96-well plate. At 70% confluence, the medium was replaced with OptiMem (Gibco) for 24 h followed by treatment. Subsequently, 20 ml CellTiter (Promega, Madison, WI, USA) was added to each well, and after incubation for 1-3 h the optical density was measured at 490 nm. Cell viability, in percentage, was normalized to untreated cells. Each experiment was repeated at least three times.
Staining of apoptotic nuclei and caspase-3 activity assay Cells (100 000) were seeded in chamber slides (B.D. Falcon, Franklin Lakes, NJ, USA) and incubated in the presence or absence of phenoxodiol (10 mg/ml) for 24 h. Subsequently, Hoechst staining was performed according to the manufacturer's instructions (Vybrant Apoptosis Assay Kit #5, Molecular Probes, Eugene, OR, USA). Caspase-3 activity was determined in duplicate on 50 mg of protein lysate by using the CaspACEt Assay System according to the manufacturer's protocol (Promega).
Preparation of cell lysates and measurement of protein concentration
Protein was prepared as previously described . Cells (1 000 000) were plated in 6-or 10-cm dishes. Once the cells reached 70% confluence, the medium was changed to OptiMem for 24 h. Subsequently, cells were treated with 500 ng/ml anti-Fas or 10 mg/ml phenoxodiol (NV06) or vehicle and incubated for 24 h. Cells were scraped, pelleted at 300 Â g for 10 min, resuspended in lysis buffer (1% NP40 and 0.1% SDS in PBS) and incubated for 20 min on ice. The cell lysate was centrifuged at 14 000 r.p.m. using a C3i centrifuge (AC1.14 rotor, SOCIETE JOUAN, Winchester, VI, USA), for 10 min. The supernatant was collected and stored until further use at À401C. A cocktail of protease inhibitors was added to the supernatant prior storage. Protein concentration was determined by BSA Calibration Assay (Pierce, Rockford, IL, USA) as previously described (Gutierrez et al., 1999) .
Colony formation
Primary ovarian cancer cells were seeded in 35 mm Petri dishes and treated with phenoxodiol for 4 h. Following treatment, the cells were maintained in regular media. Colonies were stained with crystal violet after 10 days. Only colonies of more than 30 cells were counted. The average of three independent experiments was calculated.
Western blot analysis
Protein (20 mg) were denatured in sample buffer (2.5% SDS, 10% glycerol, 5% b-mercapto-ethanol, 0.15 m Tris (pH ¼ 6.8) and 0.01% bromophenol blue) and subjected to 10 or 12% SDS-PAGE. Proteins were transferred to PVDF membranes (Immobilon, Millipore, Bedford, MA, USA) at 100 V for 105 min. Subsequently, the membranes were blocked for 1 h in 5% milk in PBS with 0.5% Tween-20 (PBS-T) and incubated overnight at 41C in primary antibody in PBS-T with 1% milk. The following antibodies and concentrations were used: 1 : 10 000 rabbit anti-actin (Sigma), 1 : 1000 rabbit anti-Flip (Upstate Biotechnology, Charlottesville, VI, USA), 1 : 10 000 mouse anti-Fas-Ligand (Transduction Laboratories, San Jose, CA, USA), 1 : 1000 mouse anti-Fas (B10, Santa Cruz, Santa Cruz, CA, USA), 1 : 1000 mouse anti-caspase-8 (Ab-3, Oncogene San Diego, CA, USA), 1 : 5000 mouse anticaspase-9 (R&D Systems, Minneapolis, MN, USA), 1 : 2000 rabbit anti-Akt (Cell Signaling, Beverly, MA, USA), 1 : 1000 mouse anti-Xiap and 1 : 5000 mouse anti-FADD (PharMingen). After three washes with PBS-T, membranes were incubated for 1 h at room temperature in 1 : 10 000 horse anti-mouse or goat anti-rabbit, both HRP labelled (Vector, Burlingame, CA, USA). Finally, proteins were visualized using enhanced chemiluminescence (Pierce).
Xenografts
Subconfluent (80%) flasks of A2780 ovarian cancer cells were trypsinized, washed in Hanks balanced salt solution (Sigma) and resuspended in the same buffer at a density of 2 Â 10 7 cells/ ml. Athymic nu/nu BALB/c mice were s.c. inoculated with 2 Â 10 6 A2780 cells bilaterally midway along the dorsal surface. For the treatment group (n ¼ 10), therapy commenced 8 days postinoculation. Phenoxodiol was formulated as a suspension in 1% carboxymethyl cellulose (CMC) and delivered i.p., every day for 6 days (qd Â 6). Treatment commenced on day 8 postinoculation and tumor measurements commenced on day 12. Control group (n ¼ 10) received 1% CMC vehicle. Tumors were measured every third day in two dimensions, length (a) and width (b), using calipers. Tumor weight (W) was calculated by the formula W ¼ ab 2 /2, where a is the longer of the two measurements (O'Dwyer et al., 1994) . Tumor proliferation curves were analysed with respect to maximal tumor inhibition (treated/control, T/C) and growth delay (difference in time (days) for test tumor to double the initial tumor volume minus the same period required for the control group to reach these parameters).
Statistics
Statistical analysis was performed using Student's t-test or ANOVA analysis. Analysis of data and graphic utilized GraphPad PRISM software (version 2) (San Diego, CA, USA).
